AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32019584
Drug: Complementary horse-assisted
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary horse-assisted therapy (cHAT)
Trial: 32019584
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU-only)
Trial: 35944269
Drug: Brief psychoeducation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychoeducation intervention added to treatment-as-usual (n = 24)
Trial: 35944269
Drug: Treatment-as-usual (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (control group, n = 27)
Trial: 32684463
Drug: Stepwise reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise reduction in milk allowance (STEP: 8 L/d of MR from d 14 to 28; 5 L/d from d 29 to 42; 4 L/d from d 43 to 49; 2 L/d from d 50 to 56 of age)
Trial: 32684463
Drug: Conventional flat-rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional flat-rate milk allowance (CON: 6.5 L/d of MR from d 14 to 42; 4 L/d from d 43 to 49; 2 L/d from d 50 to 56 of age)
Trial: 32684463
Drug: Restricted portion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted portion size (RES: maximum milk portion size of 2.3 L/portion)
Trial: 32684463
Drug: UNRES treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UNRES treatment among CON calves
Trial: 32959058
Drug: Bortezomib-containing chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib-containing chemotherapy (ADEB)
Trial: 32470389
Drug: More-intensive renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More-intensive renal replacement therapy (hemodialysis or sustained low-efficiency dialysis six times per week or continuous venovenous hemodiafiltration at 35 mL/kg per hour)
Trial: 32470389
Drug: Less-intensive renal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-intensive renal replacement therapy (hemodialysis or sustained low-efficiency dialysis three times per week or continuous venovenous hemodiafiltration at 20 mL/kg per hour)
Trial: 32173464
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 500 mg
Trial: 32173464
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 1200 mg
Trial: 32173464
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 1200 mg (PD-L1-positive)
Trial: 32173464
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 1200 mg (PD-L1-high)
Trial: 32173464
Drug: Treatment-related adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related adverse events leading to discontinuation
Trial: 34855648
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium patches (150 mg/day, increased to 225 mg/day)
Trial: 34855648
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium patches
Trial: 33683659
Drug: Targeted cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted cancer drugs as monotherapies
Trial: 33683659
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies with targeted cancer drugs
Trial: 32485781
Drug: 880 μg
RxNorm normalized name: mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 880 μg fluticasone furoate administered intranasally
Trial: 35527579
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy (Control group)
Trial: 33141477
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide econazole cream (TAEC)
Trial: 36448744
Drug: Intralesional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroid
Trial: 32773223
Drug: Triglyceride (TG)
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride (TG) levels ≥150 mg/dL
Trial: 35894933
Drug: Tofogliflozin 20
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tofogliflozin 20 mg once daily
Trial: 35377878
Drug: Integrated mass
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated mass drug administration (MDA) for STH and mass dog rabies vaccination (MDRV)
Trial: 36328878
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (twice a week for twelve weeks, 60 min sessions including warm-up, progressive resistance training, and cool-down)
Trial: 36328878
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (twice a week for twelve weeks)
Trial: 32816521
Drug: Walking boot
RxNorm normalized name: Booty Goo
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Walking boot treatment
Trial: 32814997
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg every 2 weeks (Q2W)
Trial: 32814997
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg every 4 weeks (Q4W)
Trial: 36372613
Drug: Anthocyanins (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanins (320 mg/d for 24 weeks)
Trial: 35962334
Drug: Multi-session Cognitive
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-session Cognitive Behavioural Therapy (CBT)
Trial: 32729897
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg every 4 weeks
Trial: 32729897
Drug: Faricimab 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab 6.0 mg every 12 weeks
Trial: 32729897
Drug: Faricimab 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab 6.0 mg every 16 weeks
Trial: 32729897
Drug: Faricimab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab (both dosing schedules)
Trial: 36420523
Drug: Maqui berry-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maqui berry-based nutraceutical (MBN) supplementation, 1,000 mg/day for 30 days
Trial: 34857236
Drug: L. reuteri
RxNorm normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. reuteri DSM 17938
Trial: 32406284
Drug: Herbal creams
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal creams (Centella asiatica, Cucumis sativus, Thunbergia laurifolia) and commercial moisturizing cream
Trial: 32406284
Drug: Cucumis sativus
RxNorm normalized name: CUCUMIS SATIVUS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cucumis sativus cream
Trial: 32962673
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injection into the wound at 4 and 12 postoperative days
Trial: 32127657
Drug: Plerixafor +
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor + standard mobilization (G‐CSF ± chemotherapy)
Trial: 36096929
Drug: Age, BMI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, BMI, hypertension, dyslipidemia, total fat area (TFA), visceral fat area (VFA), visceral‐to‐subcutaneous fat ratio (VSR), waist circumference (WC)
Trial: 32014311
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group with individualized protamine titration based on ACT measurements
Trial: 32014311
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with standard protamine infusion of 1.3 mg per 1 mg (100 U) of heparin
Trial: 34464242
Drug: Budesonide/formoterol (Bud
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (Bud + Form; 400/12 µg BID)
Trial: 34464242
Drug: Fluticasone/salmeterol (Flu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/salmeterol (Flu + Salm; 250/50 µg BID)
Trial: 34464242
Drug: Formoterol only
RxNorm normalized name: Formoterol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol only (Form; 12 µg BID)
Trial: 36179772
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (VKAs) among adherent patients
Trial: 36179772
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOACs) among adherent patients
Trial: 33851966
Drug: NP202, 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP202, 1000 mg, daily for 3 months
Trial: 35064715
Drug: Community-based multi-month
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based multi-month dispensing (MMD) of antiretroviral treatment (ART) with options for 3-monthly or 6-monthly dispensing.
Trial: 33957389
Drug: Vinpocetine 10
RxNorm normalized name: vinpocetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine 10 mg oral
Trial: 33957389
Drug: Vinpocetine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine 20 mg oral
Trial: 33957389
Drug: Vinpocetine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine 60 mg oral
Trial: 33957389
Drug: Vinpocetine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine 20 mg oral three times a day (one-month open label)
Trial: 32403130
Drug: 12-week intensive
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week intensive intervention comprising lifestyle approaches and treatment with insulin glargine, metformin, and dapagliflozin
Trial: 33663316
Drug: Dapoxetine taste-masked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine taste-masked oral thin films (OTFs) with pullulan, glycerol, AmberLite, and dapoxetine (30 mg)
Trial: 36381457
Drug: Half-saline (HS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-saline (HS) irrigation solution
Trial: 36381457
Drug: Normal-saline (NS)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-saline (NS) irrigation solution
Trial: 33257672
Drug: SOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOX regimen (3 cycles of tegafur gimeracil oteracil potassium capsule plus oxaliplatin)
Trial: 36469329
Drug: Housing remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing remediation or trash cleanup treatment
Trial: 33961292
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside (LDAC) plus tosedostat (LDAC-T)
Trial: 33961292
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside (LDAC)
Trial: 33996039
Drug: Interviewer-administered seven-day
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered seven-day semi-quantitative food frequency questionnaire (7-d SQFFQ)
Trial: 32321570
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR-NTX) before release
Trial: 32321570
Drug: Enhanced XR-NTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced XR-NTX (mobile medical treatment post-release)
Trial: 32321570
Drug: XR-NTX (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-NTX (standard referral to community treatment program post-release)
Trial: 32507439
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder supplementation (400 mg per tablet, 4 tablets daily for 12 weeks)
Trial: 32507439
Drug: Placebo (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (400 mg starch per tablet, 4 tablets daily for 12 weeks)
Trial: 34323454
Drug: Sphenopalatine ganglion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sphenopalatine ganglion block (SPGB) in treatment group A
Trial: 34737187
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg daily for 5 weeks after 2 weeks of titration)
Trial: 34016825
Drug: Centrifuged adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrifuged adipose tissue injection
Trial: 34016825
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection of centrifuged adipose tissue (control)
Trial: 32404059
Drug: Community-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based intervention (up to three in-home visits, monthly group wellness program, monthly case conferencing, care coordination)
Trial: 34559090
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg daily for 10 days, then 20 mg daily for 21 days
Trial: 34559090
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same shape and size as memantine tablets)
Trial: 32491932
Drug: Cabozantinib in
RxNorm normalized name: Product containing cabozantinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib in combination with atezolizumab
Trial: 36251140
Drug: Naoxintong Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naoxintong Capsule (1.2 g orally, twice a day)
Trial: 33420602
Drug: Valerian extract
RxNorm normalized name: valerian extract
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian extract (530 mg for 30 nights)
Trial: 33420602
Drug: Placebo (530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (530 mg for 30 nights)
Trial: 32845475
Drug: Endobronchial coils
RxNorm normalized name: BOIL-EASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial coils treatment
Trial: 34326642
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + CBT
Trial: 34326642
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Bupropion
Trial: 34326642
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Bupropion + Brain Stimulation
Trial: 33954859
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of orthokeratology and 0.01% atropine (OKA group)
Trial: 32756204
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow (NHF) therapy with room air only and no supplemental oxygen
Trial: 32756204
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask oxygen administration
Trial: 33788453
Drug: Sufentanil patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil patient-controlled intravenous analgesia plus sham EA (without stimulation)
Trial: 35358455
Drug: Anetumab ravtansine
RxNorm normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anetumab ravtansine (6.5 mg/kg on day 1 of each 21-day cycle)
Trial: 35358455
Drug: Vinorelbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (30 mg/m2 once every week)
Trial: 33637926
Drug: Scale and
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scale and Polish (S&P) 6-monthly
Trial: 33637926
Drug: Scale and
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scale and Polish (S&P) 12-monthly
Trial: 33637926
Drug: Usual Oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Oral Hygiene Advice (OHA)
Trial: 36103212
Drug: High dosing
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosing grape seed flour (GSF ≈ 1 g/kg)
Trial: 35904063
Drug: Oral carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral carvedilol 5 mg bid (twice per day)
Trial: 34297363
Drug: Prebiotic inulin‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic inulin‐type fructans (ITF) 16 g/d
Trial: 34297363
Drug: Control supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control supplement (maltodextrin) 16 g/d
Trial: 38295317
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (CT)
Trial: 34558200
Drug: Milvexian (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (4, 20, 60, 200, 300, or 500 mg)
Trial: 34558200
Drug: Milvexian (once-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (once- or twice-daily for 14 days)
Trial: 34558200
Drug: Milvexian (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (various doses)
Trial: 34558200
Drug: Milvexian (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (200 and 500 mg)
Trial: 34728476
Drug: Inhaled ciclesonide
RxNorm normalized name: ciclesonide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily)
Trial: 34728476
Drug: Placebo (metered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (metered dose inhaler and nasal saline)
Trial: 36116516
Drug: Ultra-low-dose quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose quadruple combination therapy
Trial: 33331916
Drug: Once-weekly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly oral azithromycin for 48 weeks
Trial: 32171328
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - Structured Material for Therapy (SMART), 6-week intervention
Trial: 32171328
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - SMART
Trial: 35650629
Drug: Immediate online
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate online assessment and subsequent sector-independent treatment coordination (ASSIST)
Trial: 32608096
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard community treatment)
Trial: 35803894
Drug: Internet-based psychodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based psychodynamic therapy (IPDT)
Trial: 34048587
Drug: Lower serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower serum ferritin levels (<100 ng/mL)
Trial: 34048587
Drug: Ferritin levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin levels above 194 ng/mL
Trial: 32617701
Drug: American ginseng
RxNorm normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: American ginseng 1000 mg per day for 8 weeks
Trial: 33534516
Drug: Weekly empathic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly empathic communication email reminders
Trial: 33403940
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg of extended-release niacin orally once daily for 24 weeks
Trial: 35301911
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MCE and HIFE
Trial: 32341641
Drug: Nebulized glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glycopyrrolate (GLY) 25 µg twice daily
Trial: 32696585
Drug: Cobimetinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobimetinib (10 mg single oral dose)